(Q36371451)

13 August 2017

1 reference

title

Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature (English)

1 reference

13 August 2017

0 references

Annabelle A Okada

1

1 reference

13 August 2017

publication date

1 September 2005

1 reference

Ocular Immunology and Inflammation

13 August 2017

published in

1 reference

13 August 2017

volume

13

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

335-351

1 reference

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Immunosuppressive Therapy for Severe Chronic Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

A controlled trial of azathioprine in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Azathioprine in Behcet's syndrome: effects on long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Idiopathic recurrent neuroretinitis: effects of long-term immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Use of methotrexate in the management of sight-threatening uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Low-dose methotrexate therapy for ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Clinical pharmacokinetics of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Mycophenolate mofetil for the treatment of scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Successful treatment of serpiginous choroiditis with alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Episcleritis and scleritis: clinical features and treatment results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Diagnosis and management of systemic Wegener's granulomatosis presenting with anterior ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Studies on the pharmacokinetics of chlorambucil and prednimustine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Treatment and visual prognosis in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Short-term chlorambucil for refractory uveitis in Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Twenty cases of sympathetic ophthalmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral vs Sandimmune

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Low dose cyclosporin A therapy in chronic posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Open noncontrolled multicenter long-term trial with ciclosporin in endogenous non-infectious uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Cyclosporin A therapy in refractory non-infectious childhood uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Cyclosporin in the treatment of severe chronic idiopathic uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Short term cyclosporin A treatment of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Cyclosporine effects on optic nerve and retinal vasculitis in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Cyclosporin-A therapy in severe uveitis of Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Long-term therapy with low dose cyclosporin A in ocular Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Cyclosporine-A in the treatment of serpiginous choroiditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Cyclosporin therapy for severe scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Use of cyclosporin in the management of steroid dependent non-necrotising scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Preclinical and clinical study of FK506 in uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Treatment of ocular cicatricial pemphigoid with tacrolimus (FK 506).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

An overview of the interferon system: signal transduction and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Side effects of alpha interferon in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940590951034

10.1080/09273940590951034

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference